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and incidences of CIN and FN were compared by day of 
pegfilgrastim use.
Results The analysis included 95 same-day patients and 
97 next-day patients. Despite similar ANC at baseline, 
ANC at nadir was higher among next-day patients than 
same-day patients. Mean AOC of ANC (cutoff 0.5 × 109/L) 
among next-day patients was lower by 0.30 (95 % confi-
dence interval: 0.16, 0.43) 109/L × day than same-day 
patients in cycle 1. Next-day patients had lower incidences 
of CIN than same-day patients, but there were no signifi-
cant differences in incidences of FN.
Conclusions Patients who received pegfilgrastim the day 
after chemotherapy had less severe and shorter suppression 
of ANC than patients who received pegfilgrastim the same 
day as chemotherapy.
Keywords Area over the curve · Chemotherapy-
induced neutropenia · Febrile neutropenia · Next-day 
administration · Pegfilgrastim · Same-day administration
Introduction
Neutrophils, the most abundant leukocytes in circulation, 
play a crucial role in innate immune responses against 
infections [1]. Cytotoxic chemotherapy suppresses the 
hematopoietic system and may lead to chemotherapy-
induced neutropenia (CIN), a condition that makes patients 
vulnerable to potentially life-threatening infections [2]. 
Following initiation of myelosuppressive chemotherapy, 
absolute neutrophil count (ANC) follows a trajectory that 
includes a decline to its lowest point (the nadir) and subse-
quent rise as the bone marrow recovers [3]. Lower ANC (or 
leukocytes) at nadir and longer duration of severe CIN (or 
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Purpose Risk of infection increases with severity and 
duration of chemotherapy-induced neutropenia (CIN). 
Pegfilgrastim is approved for use on the day after chemo-
therapy to reduce incidence of infection, as manifested by 
febrile neutropenia (FN), in patients receiving myelosup-
pressive chemotherapy. In this study, we compared severity 
and duration of absolute neutrophil count (ANC) suppres-
sion in patients who received pegfilgrastim on the same day 
as chemotherapy versus the next day.
Methods We combined individual patient data from four 
Amgen-sponsored clinical trials in which patients with 
cancer were randomized to receive pegfilgrastim either the 
same day as chemotherapy or the next day. Severity and 
duration of ANC suppression were calculated using area 
over the curve (AOC, the area over the ANC–time response 
curve and below a given clinical threshold). AOC of ANC 
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leukopenia) have been shown to be associated with higher 
risk of infection [4–6].
Neutropenia blunts the inflammatory response to nascent 
infections and reduces the signs and symptoms of infec-
tion; therefore, the only sign of infection in the presence of 
neutropenia is often fever [2]. Febrile neutropenia (FN), the 
combination of neutropenia and fever, is a serious toxicity 
of myelosuppressive chemotherapy that can lead to chem-
otherapy dose delays and reductions as well as increased 
morbidity, mortality, and healthcare resource use [7–9].
Granulocyte colony-stimulating factor (G-CSF) regu-
lates the production of neutrophils within the bone marrow 
and induces proliferation and differentiation of neutrophil 
precursors [10, 11]. Pegfilgrastim (Neulasta®, Amgen Inc., 
Thousand Oaks, CA, USA) is a pegylated recombinant 
human G-CSF that is indicated to decrease the incidence of 
infection, as manifested by FN, in patients with non-mye-
loid malignancies receiving myelosuppressive anti-cancer 
drugs [12, 13].
Neulasta® prescribing information specifies that pegfil-
grastim should not be administered between 14 days before 
and 24 h after administration of chemotherapy [13]. Theo-
retically, the simultaneous administration of exogenous 
G-CSF and chemotherapy may lead to an increased pool of 
neutrophil precursors susceptible to destruction by chemo-
therapy, leading paradoxically to an increased risk of neu-
tropenia [14, 15]. Nevertheless, some patients still receive 
pegfilgrastim on the same day as chemotherapy rather than 
the next day [16–18].
In the current study, we pooled individual patient data 
from four Amgen-sponsored clinical trials in which patients 
were randomized to receive pegfilgrastim on the same day 
as chemotherapy versus the next day. The objectives of 
this study were to compare several metrics for severity and 
duration of ANC suppression and incidence proportions of 
CIN and FN among patients who received pegfilgrastim on 
the same day as chemotherapy versus the next day.
Materials and methods
Study design and data source
The current study is a secondary analysis of individual 
patient data collected in four randomized phase 2 clinical 
trials sponsored by Amgen Inc. The trials were conducted 
between 2003 and 2005 in patients with non-Hodgkin’s 
lymphoma, breast cancer, relapsed or refractory ovarian 
cancer, and advanced or metastatic non-small cell lung 
cancer. The primary objective of the trials was to provide 
data on the safety and efficacy of pegfilgrastim admin-
istered on the same day as chemotherapy (within 24 h of 
chemotherapy completion) versus the next day (24 h after 
chemotherapy completion). The primary efficacy endpoint 
of all four trials was duration of grade 4 neutropenia. Cri-
teria for the inclusion of these four trials in this analysis 
are shown in Supplementary material 1. Key information 
regarding these four trials is summarized in Supplementary 
material 2. In three of four trials (Amgen studies 20020134, 
20020778, and 20030123), chemotherapy was admin-
istered only on day 1 of the chemotherapy cycle, and the 
same-day and next-day patients received pegfilgrastim on 
day 1 and day 2 of the cycle, respectively. In Amgen study 
20030122, chemotherapy was administered over the first 
5 days of the chemotherapy cycle, and the same-day and 
next-day patients received pegfilgrastim on day 5 and day 6 
of the cycle, respectively (Supplementary material 2).
Study population
Patients were included in this analysis if they were enrolled 
in one of the four aforementioned randomized clinical tri-
als and met all of the following additional inclusion crite-
ria: baseline ANC ≥ 1500/µL at initiation of chemotherapy, 
ANC measured at least four times per cycle in at least one 
cycle of the chemotherapy course under study, and normal 
body temperature (<38 °C) at initiation of chemotherapy. 
Patients were excluded if they had an active infection 
that required treatment with anti-infectives within 72 h of 
chemotherapy, received prophylactic antibiotics, received 
pelvic irradiation or radiation therapy extending beyond a 
single involved field within 4 weeks of chemotherapy ini-
tiation, or had a prior malignancy in the previous 5 years.
Patients in two of the included clinical trials (Amgen 
studies 20020778 and 20030122) had ANC measured 
at least four times per cycle in both cycle 1 and cycle 3. 
Patients in the other two trials (Amgen studies 20020134 
and 20030123) had ANC measured at least four times per 
cycle only in cycle 1. All the ANC-related analyses in the 
current study were conducted in cycles in which ANC was 
measured at least four times per cycle.
Endpoints
The primary endpoint of this study was area over the ANC–
time response curve (AOC). AOC of ANC is the area above 
the ANC–time response curve and below the thresholds of 
0.5 × 109/L or 1.0 × 109/L in a given chemotherapy cycle 
(shown graphically in Fig. 1). AOC of ANC measures both 
severity and duration of neutropenia. The more severe and 
the longer the duration of neutropenia, the higher the AOC. 
The thresholds of 0.5 × 109/L and 1.0 × 109/L are based 
on the Common Terminology Criteria for Adverse Events 
(CTCAE): an ANC < 0.5 × 109/L is categorized as grade 
4 neutropenia, while an ANC between 0.5 × 109/L and 
1.0 × 109/L is categorized as grade 3 neutropenia [19].
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The secondary endpoints of this study were ANC 
at nadir, time to ANC nadir, and incidence proportions 
of grade 4 CIN (ANC < 0.5 × 109/L), grade 3/4 CIN 
(ANC < 1.0 × 109/L), grade 4 FN, and grade 3/4 FN 
within a chemotherapy cycle. Grade 4 and grade 3/4 FN 
were defined as an infectious episode (body temperature 
≥38.2 °C, infection-related hospitalization, or infection-
related adverse event) occurring on the same day or within 
1 day of grade 4 or grade 3/4 neutropenia, respectively.
Statistical analysis
Descriptive analyses were conducted to characterize demo-
graphics, disease characteristics, and chemotherapy treat-
ments in the overall study population and in each of the 
treatment groups (same-day versus next-day pegfilgrastim 
use). The two-sample t test was used to assess differences 
in continuous variables, and the Chi-square test was used 
to assess differences in categorical variables between the 
treatment groups. No multiplicity adjustment was used, 
and p values should be considered nominal. Body surface 
area was calculated using the Mosteller formula [20]. Risk 
of FN for each chemotherapy regimen was based on the 
National Comprehensive Cancer Network (NCCN) guide-
lines [21]. For regimens that remain unclassified, FN inci-
dence in the placebo arms (no G-CSF) of Amgen-spon-
sored clinical trials and FN risk reported in the literature 
were used to determine FN risk category [22].
Baseline ANC values, ANC at nadir, and time to ANC 
nadir were described by treatment group for each cycle 
with ≥4 ANC measurements (cycles 1 and 3). The log-
linear interpolation technique [23] was used to derive ANC 
on days without a measurement using the adjacent ANC 
measurements from each patient. ANC nadir was the low-
est ANC value that occurred during the chemotherapy 
cycle. Time to ANC nadir was calculated as the number of 
days from chemotherapy initiation to ANC nadir. Distribu-
tions of all ANC metrics were skewed; thus, the Wilcoxon 
rank sum test was used to compare the differences between 
the two treatment groups. Differences in the distribution 
Fig. 1  ANC trajectory in 
patients who received peg-
filgrastim on the same day 
as chemotherapy versus the 
next day. a ANC trajectory 
in cycle 1. Data are from 
eligible patients in Amgen 
studies 20020134, 20020778, 
20030122, and 20030123. b 
ANC trajectory in cycle 3. 
Data are from eligible patients 
in Amgen studies 20020778 
and 20030122. Red squares 
represent daily median ANC 
values for patients who received 
pegfilgrastim on the same day 
as chemotherapy. Green squares 
represent daily median ANC 
values for patients who received 
pegfilgrastim on the day after 
chemotherapy. Error bars 
represent Q1 and Q3 of daily 
ANC values. AOC is the area 
above the ANC-time response 
curve and below a given clinical 
threshold (ANC < 1.0 × 109/L 
or ANC < 0.5 × 109/L). The 
cross-hatched area represents 
AOC for ANC < 1.0 × 109/L. 
ANC values are shown on a 
natural logarithmic scale. Days 
are numbered from chemother-
apy initiation: day 1 is the day 
of chemotherapy; day 2 is the 
day after chemotherapy. ANC 
absolute neutrophil count; AOC 
area over the curve; Q1 quartile 
1; Q3 quartile 3
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of time to ANC nadir (<7, 7, 8, and >8 days) between the 
two groups were tested using the Chi-square test or Fisher’s 
exact test (if expected cell frequency was <5). A sensitiv-
ity analysis was performed to compare time to ANC nadir 
for the studies in which chemotherapy was administered 
only on day 1 of the chemotherapy cycle (Amgen studies 
20020134, 20020778, and 20030123), and a separate sen-
sitivity analysis was performed to compare time to ANC 
nadir for the study in which chemotherapy was admin-
istered over the first 5 days of the chemotherapy cycle 
(Amgen study 20030122).
AOC of the ANC–time response curve (below the 
thresholds of 0.5 × 109/L or 1.0 × 109/L) was calculated 
using the Riemann sum method, assuming ANC values to 
be constant within each day [24]. Due to the large propor-
tion of patients with an AOC of 0 (e.g., 35.8 % of same-
day patients and 51.0 % of next-day patients had an AOC 
of 0 below the threshold of 0.5 × 109/L in cycle 1), median 
AOC might not be meaningful. Mean AOC of ANC was 
therefore calculated for each group as were differences in 
mean AOC of ANC between patients who received pegfil-
grastim on the same day as chemotherapy versus the next 
day. Differences in mean AOC were calculated in cycle 
1 or cycle 3 separately using linear regression and in the 
two cycles combined using linear mixed-effect regression 
to control for within-patient and within-study correlations. 
Age (as a linear continuous variable) and Eastern Coop-
erative Oncology Group (ECOG) performance status (0, 
1, and 2–3 as a categorical variable), the covariates with 
imbalanced distributions between the two groups, were 
controlled for in the adjusted model. A bootstrap procedure 
was used to estimate the 95 % confidence intervals (CIs) 
for mean AOC difference. One thousand bootstrap samples 
were first selected from AOC estimates using stratified 
random sampling (by day of pegfilgrastim use and study) 
with replacement. Mean AOC differences by day of peg-
filgrastim use within each of the 1000 replicates were then 
estimated. The 2.5th and 97.5th percentiles of the boot-
strap samples were used as the 95 % CIs of the mean AOC 
difference.
Incidence proportions of CIN and FN within a chemo-
therapy cycle were calculated by day of pegfilgrastim use 
for cycles 1 and 3. A generalized linear mixed model with 
logit link function was used to compare the odds of CIN 
and FN in next-day versus same-day patients, adjusting 
for age (as a linear continuous variable) and ECOG per-
formance status (0, 1, and 2–3 as a categorical variable) in 
cycle 1, cycle 3, and cycles 1 and 3 combined. Within-study 
correlation and within-patient correlation in the combined 
analysis of cycles 1 and 3 were controlled for by including 
random intercepts in the mixed model.
Results
Clinical trials and patients
Four randomized phase 2 clinical trials were identified in 
which patients were allocated to receive pegfilgrastim on 
the same day as chemotherapy versus the next day. A total 
of 192 patients in these trials were eligible for inclusion in 
the current study: 95 patients who received pegfilgrastim 
on the same day as chemotherapy and 97 who received 
pegfilgrastim on the next day. Patient disposition by inclu-
sion and exclusion criteria for each of the studies and for 
all studies combined is shown in Table 1.
Table 1  Patient disposition after applying each of the inclusion/exclusion criteria
All numbers indicate number of patients
ANC absolute neutrophil count, NHL non-Hodgkin’s lymphoma; NSCLC non-small cell lung cancer









Same day Next day Same day Next day Same day Next day Same day Next day Same day Next day
Patients enrolled and received 
assigned drugs
36 39 45 43 8 11 43 44 132 137
Baseline ANC ≥ 1500/µL 36 37 45 43 8 11 43 44 132 135
Normal baseline body  
temperature
35 37 45 43 8 11 43 44 131 135
No history of cancer within  
the last 5 years
30 30 32 32 6 7 38 34 106 103
No history of chemotherapy 30 30 32 32 5 7 38 34 105 103
No recent radiation therapy 30 30 32 31 5 7 34 33 101 101
ANC measured ≥4 times in 
cycle 1
29 29 32 30 5 6 29 32 95 97
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Of the eligible patients, most were female (67.7 %), 
white (80.7 %), and had an ECOG performance status of 
0 (54.7 %). Mean (±standard deviation [SD]) age of the 
patients was 58.9 (±12.7) years. Primary tumor types 
were breast cancer (32.3 %), non-small cell lung cancer 
(31.8 %), non-Hodgkin’s lymphoma (30.2 %), and ovar-
ian cancer (5.7 %). About half of the patients (48.4 %) had 
advanced tumors (stage IV or “extensive”). Most patients 
(62.0 %) received chemotherapy regimens with an inter-
mediate risk (10–20 %) of FN. Demographics, disease 
characteristics, and chemotherapy regimen FN risk are 
shown in Table 2. Overall, demographics and disease char-
acteristics were balanced between the same-day and next-
day groups.
ANC trajectory
ANC trajectories of the patients who received pegfil-
grastim on the same day as chemotherapy and those who 
received pegfilgrastim the next day are shown in Fig. 1. In 
Table 2  Baseline 
demographics, disease 
characteristics, and treatment 
parameters of the study 
population
BMI body mass index, BSA body surface area, ECOG eastern cooperative oncology group, FN febrile neu-
tropenia, SD standard deviation
a Two-sample t test was used to test differences for continuous variables, and Chi-square test or Fish-
er’s exact test (if expected cell frequency was <5) were used to test differences for categorical variables 
between same-day and next-day patients. No multiplicity adjustment was used and p values should be con-
sidered nominal
b Stages I, II, and III or “limited” were classified as non-advanced; stage IV or “extensive” were classified 
as advanced
c Regimens with an intermediate risk (10–20 %) of FN included: 21-day R-CHOP (cyclophosphamide, 
doxorubicin, vincristine, prednisone, and rituximab) and 21-day carboplatin and docetaxel
d Regimens with a high risk (>20 %) of FN included: 21-day TAC (docetaxel, doxorubicin, and cyclophos-
phamide) and 21-day topotecan
Overall (N = 192) Same day (N = 95) Next day (N = 97) p valuea
Sex, n (%)
 Male 62 (32.3) 31 (32.6) 31 (32.0) 0.921
 Female 130 (67.7) 64 (67.4) 66 (68.0)
Race, n (%)
 White or Caucasian 155 (80.7) 77 (81.1) 78 (80.4) 0.180
 Black or African American 21 (10.9) 13 (13.7) 8 (8.2)
 Other 16 (8.3) 5 (5.3) 11 (11.3)
Age, years
 Mean ± SD 58.9 ± 12.7 57.5 ± 12.7 60.4 ± 12.7 0.114
 ECOG performance status, n (%)
 0 105 (54.7) 58 (61.1) 47 (48.5) 0.191
 1 82 (42.7) 35 (36.8) 47 (48.5)
 2 5 (2.6) 2 (2.1) 3 (3.1)
BSA, m2
 Mean ± SD 1.86 ± 0.24 1.87 ± 0.24 1.86 ± 0.25 0.739
BMI, kg/m2
 Mean ± SD 27.34 ± 5.76 27.07 ± 5.57 27.61 ± 5.95 0.522
Primary tumor type, n (%)
 Breast cancer 62 (32.3) 32 (33.7) 30 (30.9) 0.963
 Non-small cell lung cancer 61 (31.8) 29 (30.5) 32 (33.0)
 Non-Hodgkin’s lymphoma 58 (30.2) 29 (30.5) 29 (29.9)
 Ovarian cancer 11 (5.7) 5 (5.3) 6 (6.2)
Tumor stageb, n (%)
 Non-advanced 99 (51.6) 51 (53.7) 48 (49.5) 0.560
 Advanced 93 (48.4) 44 (46.3) 49 (50.5)
Chemotherapy regimen, n (%)
 Intermediate risk of FNc 119 (62.0) 58 (61.1) 61 (62.9) 0.794
 High risk of FNd 73 (38.0) 37 (38.9) 36 (37.1)
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both cycle 1 (Fig. 1a) and cycle 3 (Fig. 1b), the ANC tra-
jectories of same-day patients and next-day patients began 
to diverge on the day after chemotherapy (day 2). ANC 
at nadir was lower among same-day patients than among 
next-day patients in both cycle 1 and cycle 3. ANC values 
returned to baseline sooner and remained higher through-
out the cycle among next-day patients than among same-
day patients in both cycles.
Key statistics of the ANC trajectory of patients in this 
study are shown in Table 3. Baseline ANC values were 
not different between same-day and next-day patients 
(p > 0.05). In contrast, ANC at nadir was significantly lower 
among same-day patients than among next-day patients in 
both cycle 1 (median [Q1, Q3]: 0.13 [0.04, 1.31] versus 0.54 
[0.11, 2.04] × 109/L, p = 0.003) and cycle 3 (median [Q1, 
Q3]: 0.07 [0.04, 0.27] versus 0.37 [0.14, 1.00] × 109/L, 
p < 0.001). Although the mean or median time to ANC nadir 
was similar between the two treatment groups in cycle 1, 
same-day patients tended to reach ANC nadir earlier than 
next-day patients: 22.1 versus 7.3 % reached ANC nadir 
within 7 days after chemotherapy in cycle 1 (Table 3). No 
significant differences in time to ANC nadir were observed 
in cycle 3 (Table 3). In the sensitivity analysis, we observed 
that same-day patients tended to reach ANC nadir earlier 
than next-day patients in cycle 1 for studies in which chem-
otherapy was administered only on day 1 of the chemo-
therapy cycle (Supplementary material 3). Only one study 
with a very small sample size (n = 11 in cycle 1, n = 7 in 
cycle 3) had chemotherapy administered over multiple days 
of the chemotherapy cycle. In this study, no difference in 
time to ANC nadir was observed between same-day and 
next-day patients (Supplementary material 4).
Area over the ANC–time response curve
AOC of ANC, a composite measure of duration and sever-
ity of ANC suppression, was significantly higher among 
same-day patients than among next-day patients (Table 4). 
In cycle 1, when ANC < 0.5 × 109/L was used as the 
threshold, mean AOC of ANC was higher by 0.30 (95 % 
CI 0.16, 0.43) 109/L × day among same-day patients than 
among next-day patients. When ANC < 1.0 × 109/L was 
used as the threshold, mean AOC of ANC was higher by 
0.73 (95 % CI 0.37, 1.05) 109/L × day among same-day 
patients. In cycle 3, when both ANC < 0.5 × 109/L and 
ANC < 1.0 × 109/L were used as the thresholds, AOC was 
significantly higher among same-day patients than among 
next-day patients. Similar findings were observed in the 
analysis of cycles 1 and 3 combined (Table 4).
Chemotherapy‑induced neutropenia and febrile 
neutropenia
Incidence proportions of CIN and FN within the chemother-
apy cycle among same-day and next-day patients are shown in 
Table 5. Incidence proportion of grade 4 CIN was significantly 
Table 3  ANC trajectory in patients who received pegfilgrastim on 
the same day as chemotherapy versus the next day in cycle 1 and 
cycle 3
Analyses in cycle 1 include data from eligible patients in Amgen 
studies 20020134, 20020778, 20030122, and 20030123 and in cycle 
3 include data from eligible patients in Amgen studies 20020778 and 
20030122
Bold indicates p < 0.05
ANC absolute neutrophil count; Q1 quartile 1; Q3 quartile 3; SD 
standard deviation
a Wilcoxon rank sum test was used to test differences of baseline 
ANC, ANC at nadir, and time to nadir (continuous), and Chi-square 
test or Fisher’s exact test (if expected cell frequency was <5) was 
used to test difference of time to nadir distribution (<7 days, 7 days, 
8 days, and >8 days) between same-day versus next-day patients
b The n for each parameter (of each treatment arm) is the number of 
patients eligible for the corresponding statistics in cycle 1 or cycle 3
c No patients reached ANC nadir in <7 days in cycle 3, so <7 days 
and 7 days were combined
ANC trajectory 
metrics
Same day Next day p valuea
Cycle 1
Baseline ANC (109/L)
 Mean ± SD (nb) 8.99 ± 5.78 (94) 9.64 ± 5.98 (96)
 Median (Q1, Q3) 7.14 (4.42, 12.18) 8.08 (5.31, 13.39) 0.404
ANC at nadir (109/L)
 Mean ± SD (nb) 1.33 ± 2.32 (95) 1.83 ± 2.96 (96)
 Median (Q1, Q3) 0.13 (0.04, 1.31) 0.54 (0.11, 2.04) 0.003
Time to ANC nadir (days)
 Mean ± SD (nb) 7.52 ± 2.48 (95) 7.61 ± 1.43 (96)
 Median (Q1, Q3) 7.00 (7.00, 8.00) 7.00 (7.00, 8.00) 0.019
Time to ANC nadir distribution, n (%)
 <7 days 21 (22.1) 7 (7.3) 0.028
 7 days 40 (42.1) 43 (44.8)
 8 days 23 (24.2) 30 (31.3)
 >8 days 11 (11.6) 16 (16.7)
Cycle 3
Baseline ANC (109/L)
 Mean ± SD (nb) 8.65 ± 4.74 (30) 9.32 ± 5.33 (33)
 Median (Q1, Q3) 8.67 (4.92, 12.14) 7.99 (4.34, 13.90) 0.549
ANC at nadir (109/L)
 Mean ± SD (nb) 0.27 ± 0.50 (30) 0.74 ± 0.93 (33)
 Median (Q1, Q3) 0.07 (0.04, 0.27) 0.37 (0.14, 1.00) <0.001
Time to ANC nadir (days)
 Mean ± SD (nb) 7.53 ± 0.73 (30) 7.70 ± 0.88 (33)
Median (Q1, Q3) 7.00 (7.00, 8.00) 7.00 (7.00, 8.00) 0.503
Time to ANC nadir distributionc n (%)
 ≤7 days 18 (60.0) 17 (51.5) 0.829
 8 days 8 (26.7) 11 (33.3)
 >8 days 4 (13.3) 5 (15.2)
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lower among next-day patients than among same-day patients 
in both cycle 1 (49.0 versus 64.2 %, adjusted odds ratio [OR] 
[95 % CI] 0.23 [0.09, 0.62]) and cycle 3 (57.6 versus 83.3 %, 
adjusted OR [95 % CI] 0.19 [0.04, 0.79]). In cycles 1 and 3 
combined, next-day patients had significantly lower odds of 
having grade 4 CIN (adjusted OR [95 % CI] 0.23 [0.10, 0.49]).
Incidence proportion of grade 3/4 CIN was not signifi-
cantly different between same-day versus next-day patients 
in cycles 1 and 3 separately: cycle 1 (65.6 versus 72.6 %, 
adjusted OR [95 % CI] 0.48 [0.17, 1.35]) and cycle 3 (72.7 
versus 93.3 %, adjusted OR [95 % CI] 0.13 [0.02, 1.02]). 
However, in cycles 1 and 3 combined, the incidence pro-
portion of grade 3/4 CIN was statistically lower among 
next-day patients than among same-day patients (adjusted 
OR [95 % CI] 0.36 [0.15, 0.87]).
No statistically significant differences were observed 
between same-day and next-day patients in the incidence 
proportions of grade 4 FN or grade 3/4 FN in cycle 1, cycle 
3, or cycles 1 and 3 combined (Table 5).
Discussion
Several randomized, placebo-controlled clinical trials 
have shown that patients with cancer who were treated 
with chemotherapy and prophylactic G-CSF experienced 
substantially less severe suppression of ANC, more rapid 
recovery of ANC, and lower incidence of infection (charac-
terized by FN) than patients who did not receive prophylac-
tic G-CSF [12, 25, 26]. In the current study, patients who 
received pegfilgrastim prophylaxis on the day after chem-
otherapy (24 h after chemotherapy completion) had a less 
severe fall in ANC and more rapid recovery of ANC than 
patients who received pegfilgrastim on the same day as 
chemotherapy (within 24 h of chemotherapy completion).
Previous studies have provided some evidence that 
patients with cancer who had lower ANCs and longer dura-
tion of severe CIN following chemotherapy were at higher 
risk of developing infection [4, 27]. Each unit increase 
in AOC of ANC (109/L × day) below the threshold of 
ANC < 0.5 × 109/L was found to be associated with a sig-
nificantly increased risk of infection-related hospitaliza-
tion (hazard ratio [95 % CI] 1.98 [1.35, 2.90]) [28]. In this 
study, we did not find a statistically significant difference in 
the incidences of FN between patients who received peg-
filgrastim prophylaxis on the same day as chemotherapy 
versus the next day. This is likely due to the limited statisti-
cal power of the study. The study included 192 patients and 
had about 30 % power to detect a relative risk of 0.6.
Burris et al. [29] analyzed ANC data from the same four 
clinical trials included in this analysis; however, the objec-
tives and analytical approaches of that study were different 
Table 4  Comparison of mean AOC of ANC in patients who received pegfilgrastim on the same day as chemotherapy versus the next day in 
cycle 1 and cycle 3
Mean AOC difference = mean AOC in same-day patients−mean AOC in next-day patients; analyses in cycle 1 include data from eligible 
patients in Amgen studies 20020134, 20020778, 2003012, and 20030123 and in cycle 3 include data from eligible patients in Amgen studies 
20020778 and 20030122
Bold indicates that 95 % CIs for crude oradjusted mean AOC difference do not include 0
AOC area over the curve; ANC absolute neutrophil count; CI confidence interval; ECOG Eastern Cooperative Oncology Group; SD standard 
deviation
a The n for each parameter (of each treatment arm) is the number of patients eligible for the corresponding statistics in cycle 1 or cycle 3
b Covariates included in the adjusted model were age and ECOG performance status
c Linear mixed-effect regression model was used to calculate mean AOC difference in cycles 1 and 3 combined. Within-study and within-patient 
correlations were controlled for in the analysis. Bootstrap procedure was used to derive 95 % CIs
AOC threshold Cycle Day of pegfilgrastim use Mean ± SD AOC (na) 
109/L × day
Crude Mean AOC 
Difference (95 % CI) 
109/L × day
Adjusted Mean AOCb 
Difference (95 % CI) 
109/L × day
<0.5 × 109/L Cycle 1 Same day 0.65 ± 0.65 (95) 0.31 (0.17, 0.43) 0.30 (0.16, 0.43)
Next day 0.34 ± 0.49 (96)
Cycle 3 Same day 0.74 ± 0.50 (30) 0.47 (0.28, 0.64) 0.43 (0.23, 0.61)
Next day 0.27 ± 0.33 (33)
Cycles 1 and 3c 0.33 (0.20, 0.45) 0.36 (0.22, 0.49)
<1.0 × 109/L Cycle 1 Same day 1.85 ± 1.71 (95) 0.75 (0.41, 1.04) 0.73 (0.37, 1.05)
Next day 1.10 ± 1.31 (96)
Cycle 3 Same day 2.23 ± 1.18 (30) 1.21 (0.74, 1.65) 1.11 (0.63, 1.55)
Next day 1.02 ± 0.96 (33)
Cycles 1 and 3c 0.82 (0.50, 1.12) 0.88 (0.54, 1.20)
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from the current study. Burris et al. presented ANC data, 
such as ANC nadir and incidence and duration of grade 4 
neutropenia in cycle 1, for each individual trial. We pooled 
individual patient data from the four trials and performed a 
statistical analysis of the shape of the ANC trajectories by 
using AOC of ANC. Two additional clinical trials evalu-
ated the difference between same-day and next-day pegfil-
grastim prophylaxis. Saven et al. [30] reported higher inci-
dence of grade 4 CIN among same-day patients but similar 
incidence of FN, while Belani et al. [31] reported no differ-
ence in the incidences of CIN or FN by day of pegfilgrastim 
use. Results from observational studies are also inconsistent, 
which might be explained by heterogeneous study designs, 
possible selection bias, and confounding [18, 32–35]. Also, 
most of the observational studies had relatively small sam-
ple sizes [32–35]. One recent observational study retrospec-
tively analyzed 45,592 patients (4336 same day, 32,759 next 
day) from two private US healthcare claims databases. The 
study reported that odds of FN were significantly higher 
among patients who received pegfilgrastim on the same day 
as chemotherapy versus the next day (OR [95 % CI] 1.6 [1.3, 
1.9] for cycle 1; OR [95 % CI] 1.5 [1.3, 1.6] for all cycles 
combined) [18]. The direction and magnitude of the associa-
tions reported in that study are similar to those reported here.
The 2015 update to the American Society of Clinical 
Oncology Clinical Recommendations for the Use of White 
Blood Cell (WBC) Growth Factors states that, “Evidence 
suggests that pegfilgrastim administered 1–3 days after 
chemotherapy results in a lower risk of infection than peg-
filgrastim administered on the same day as chemotherapy” 
[36]. The current version of the NCCN Guidelines® for 
Myeloid Growth Factors states that, “Beginning pegfil-
grastim the day after chemotherapy is preferred” [21]. 
The favorable ANC trajectory and lower incidence pro-
portion of CIN observed in the current study support these 
recommendations.
This study has several strengths. By performing a 
pooled analysis of clinical trial data from patients who 
Table 5  Comparison of incidence proportions of CIN and FN in patients who received pegfilgrastim on the same day as chemotherapy versus 
the next day in cycles 1 and 3
Analyses in cycle 1 include data from eligible patients in Amgen studies 20020134, 20020778, 20030122, and 20030123 and in cycle 3 include 
data from eligible patients in Amgen studies 20020778 and 20030122
Bold indicates that 95 % CIs for crude ORor adjusted OR do not include 1
CI confidence interval; CIN chemotherapy-induced neutropenia; ECOG Eastern Cooperative Oncology Group; FN febrile neutropenia; OR odds 
ratio
a Covariates adjusted in the generalized linear mixed model included age and ECOG performance status
b Generalized linear mixed model using logit link function (with random intercepts to control for the within-study and within-patient correla-
tions) was used to calculate the ORs (95 % CIs) for cycles 1 and 3 combined 
Neutropenic event Cycle Day of pegfilgrastim use Cases/patients (incidence  
proportion)
Crude OR (95 % CI) Adjusted OR (95 % CI)a
Grade 3/4 CIN Cycle 1 Same day 69/95 (72.6 %) Reference Reference
Next day 63/96 (65.6 %) 0.58 (0.22, 1.55) 0.48 (0.17, 1.35)
Cycle 3 Same day 28/30 (93.3 %) Reference Reference
Next day 24/33 (72.7 %) 0.12 (0.01, 0.95) 0.13 (0.02, 1.02)
Cycles 1 and 3b 0.41 (0.17, 0.94) 0.36 (0.15, 0.87)
Grade 4 CIN Cycle 1 Same day 61/95 (64.2 %) Reference Reference
Next day 47/96 (49.0 %) 0.31 (0.12, 0.77) 0.23 (0.09, 0.62)
Cycle 3 Same day 25/30 (83.3 %) Reference Reference
Next day 19/33 (57.6 %) 0.22 (0.06, 0.87) 0.19 (0.04, 0.79)
Cycles 1 and 3b 0.29 (0.14, 0.60) 0.23 (0.10, 0.49)
Grade 3/4 FN Cycle 1 Same day 16/95 (16.8 %) Reference Reference
Next day 10/96 (10.4 %) 0.58 (0.24, 1.40) 0.59 (0.24, 1.45)
Cycle 3 Same day 2/30 (6.7 %) Reference Reference
Next day 2/33 (6.1 %) 0.90 (0.11, 7.14) 1.02 (0.12, 8.42)
Cycles 1 and 3b 0.62 (0.28, 1.39) 0.66 (0.29, 1.49)
Grade 4 FN Cycle 1 Same day 16/95 (16.8 %) Reference Reference
Next day 9/96 (9.4 %) 0.51 (0.21, 1.27) 0.53 (0.21, 1.32)
Cycle 3 Same day 2/30 (6.7 %) Reference Reference
Next day 2/33 (6.1 %) 0.90 (0.11, 7.14) 1.02 (0.12, 8.42)
Cycles 1 and 3b 0.56 (0.25, 1.28) 0.60 (0.26, 1.38)
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were randomized to receive pegfilgrastim on the same 
day as chemotherapy or the next day, we avoided bias 
due to confounding, an issue that might affect other study 
designs. Our data included frequent measurements of 
ANC, which enabled good estimation of ANC trajectory 
and of the difference in AOC of ANC between the patients 
who received pegfilgrastim on the same day as chemo-
therapy versus the next day. Severity and duration of CIN 
were simultaneously captured by using AOC of ANC in 
this analysis, and potential covariates with imbalanced 
distributions were adjusted for when comparing AOC of 
ANC between the two treatment groups. Inclusion and 
exclusion criteria were applied in addition to the original 
criteria used in each trial (e.g., baseline ANC and body 
temperature and ANC measurement frequency within 
each chemotherapy cycle) to standardize patient selection 
in this analysis. Standardized definitions of study end-
points and covariates were also developed and applied in 
this study.
This study also has limitations. The original primary 
efficacy endpoint of the four clinical trials included in 
this analysis was duration of grade 4 neutropenia, and 
the trials were not designed to detect a difference in risk 
of infection/FN. The sample size in this pooled analy-
sis was not sufficient to detect possible difference in 
the incidence proportions of FN between patients who 
received pegfilgrastim on the same day as chemotherapy 
versus the next day. Another limitation is that patients 
in the original studies did not have frequent enough 
measurements of ANC to allow examination of the ANC 
trajectory in all cycles of chemotherapy. In addition, 
patients enrolled in the original clinical trials might not 
be representative of patients with cancer treated in rou-
tine clinical practice today; thus, the results from this 
pooled analysis of clinical trial data might have limited 
generalizability.
Conclusions
In this secondary analysis of individual patient data from 
four randomized clinical trials, we found that patients who 
received pegfilgrastim as indicated, on the day after chem-
otherapy, had less severe and less sustained suppression 
of ANC as manifested by higher ANC nadirs and smaller 
AOC of ANC than patients who received pegfilgrastim on 
the same day as chemotherapy. Next-day patients also had 
lower incidence proportions of grade 3 or 4 CIN than same-
day patients. No significant differences were observed in 
the incidence proportions of FN, likely due to the lack of 
statistical power in the study. Together, these results sup-
port administration of pegfilgrastim as indicated, on the day 
after chemotherapy.
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